A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

The long-term benefits of CAR T-cell therapy, the use of residual disease activity to direct treatment, and a novel drug ...

Explore the emerging uses and future directions of chimeric antigen receptor T-cell therapy targeting mRNA, anti-EGFRvIII, and anti-NY-ESO-1 antigens in cancer treatments.

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...

In the lab, the T-cells are modified by adding a synthetic chimeric antigen receptor (CAR). This receptor prompts the T-cells to actively destroy cancer cells, although its mechanism for ...